West Lafayette, IN, United States of America

Petinka I Vlahova

This inventor holds 27 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Crystallography. Top assignees: Salix Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., Biomed Valley Discoveries, Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Petinka I Vlahova. Retrieved from https://idiyas.com/inventor/petinka-i-vlahova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 8)

% Patents Active = 92.6

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 97(Granted Patents)

Company Filing History:

9 out of 65

Salix Pharmaceuticals, Inc.

patents

7 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

5 out of 43

Biomed Valley Discoveries, Inc.

patents

4. 3 out of 3,745

Bristol-Myers Squibb Compnay

patents

5. 2 out of 15

Sumitomo Pharma Co., Ltd.

G1 Therapeutics, Inc.

patents

8. 1 out of 8

Gi Therapeutics, Inc.

patents

9. 1 out of 946

Gilead Sciences, Inc.

Sumitomo Pharma Switzerland Gmbh

patents

13. 1 out of 1,228

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Crystalline Forms

IDO Inhibitors

Ion Channel Modulator

Morphic Forms

Cocrystals

Polymorphic Forms

Nalbuphine Hydrochloride

Rifaximin

Manufacturing Methods

Amorphous Forms

Dimethylamino

Thieno[2,3-d]pyrimidin

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735430 - Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea (2026-09-15),

2. 12655154 - Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea (2026-06-16),

3. 12421195 - Amorphous and crystalline forms of IDO inhibitors (2025-09-23),

4. 12338249 - Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea (2025-06-24),

5. 12187698 - Crystalline forms of CHClNO (2025-01-07),

6. 12139494 - Morphic forms of G1T38 and methods of manufacture thereof (2024-11-12),

7. 12129264 - Crystalline forms of a PAR4 inhibitor (2024-10-29),

8. 11390600 - Crystalline forms of CHClNO (2022-07-19),

9. 11261193 - Morphic forms of G1T38 and methods of manufacture thereof (2022-03-01),

10. 11236049 - Amorphous and crystalline forms of IDO inhibitors (2022-02-01),

11. 10738027 - Crystalline forms of CHClNO (2020-08-11),

12. 10183927 - [object Object] (2019-01-22),

13. 9676746 - [object Object] (2017-06-13),

14. 9546183 - Forms of rifaximin and uses thereof (2017-01-17),

15. 9273066 - Forms of rifaximin and uses thereof (2016-03-01),

Title: The Inventor Spotlight: Petinka I Vlahova

Introduction:

Petinka I Vlahova is a talented inventor based in West Lafayette, IN (US) who has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 20 patents, she continues to drive innovation in the treatment of cancer and beyond.

Latest Patents:

Among Vlahova's latest patents are crystalline forms of CHClNO, a compound with great potential for the treatment of cancer. Additionally, her work on morphic forms of G1T38 showcases her dedication to improving therapeutic pharmaceutical efficacy and dosage form stability.

Career Highlights:

Vlahova has honed her expertise through her tenure at reputable companies such as Salix Pharmaceuticals, Inc. and Vertex Pharmaceuticals, Inc. Her experience in these esteemed organizations has further fueled her passion for research and development in the pharmaceutical industry.

Collaborations:

Throughout her career, Vlahova has had the privilege of collaborating with accomplished professionals in the field. Some of her notable coworkers include Karen Sue Gushurst and Donglai Yang, who have contributed to the success of various projects alongside Vlahova.

Conclusion:

In conclusion, Petinka I Vlahova stands out as a prominent figure in the world of pharmaceutical innovation. Her dedication to advancing treatment options for cancer patients is reflected in her impressive patent portfolio and successful collaborations. Vlahova's work serves as a testament to the impact that inventive minds can have on improving healthcare outcomes.

Profile summary based on public USPTO records.